And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And our agenda is rather modest, despite the extended holiday weekend on this side of the pond. We plan to manicure the Pharmalot grounds, hang with our short person, promenade with the official mascots, and catch up on our reading. And what about you? This continues to be a lovely time to enjoy the great outdoors — there are beaches, lakes, and mountains to explore. You could make time for someone special or indulge in a few naps. Or prepare your bunker now that you-know-who called off peace talks. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you on Tuesday …

Most companies that pay six figures to the majority of their workers are not big banks or money managers, but biotech firms that rely on medical researchers, according to an analysis by The Wall Street Journal. Four companies in the S&P 500 paid workers in the middle of their payrolls more than $200,000, and three of them are drug makers. At Incyte (INCY), Celgene (CELG), and Vertex (VRTX) Pharmaceuticals (VRTX), the middle-earners last year made $253,000, $213,000 and $211,500, respectively.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy